This compound is a salt-like pharmaceutical intermediate, consisting of a triethylamine salt of a modified guanosine diphosphate derivative. It is primarily used in research and pharmaceutical manufacturing contexts.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 2089461-52-7
((2R,3R,4R,5R)-5-(2-Amino-7-methyl-6-oxo-3,6-dihydro-9H-purin-7-ium-9-yl)-3-hydroxy-4-methoxytetrahydrofuran-2-yl)methyl hydrogen phosphate
RNA modification intermediate
2-(3-(4-Bromo-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
pharmaceutical intermediate
2-[[3,4-Dihydro-3-methyl-2,4-dioxo-6-[(3R)-3-piperidinylamino]-1(2H)-pyrimidinyl]methyl]-benzonitrile
Alogliptin impurity reference standard
8-Chloro-6-fluoroquinazoline-2,4-diol
Pharmaceutical intermediate for quinazoline derivatives
1-(bromomethyl)-1-(trifluoromethyl)cyclopentane
Pharmaceutical intermediate compound
7-methylguanosine 5'-(trihydrogen diphosphate)
Pharmaceutical intermediate for nucleotide analogs
[(2R,3S,4R,5R)-5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-4-hydroxy-3-methoxyoxolan-2-yl]methyl phosphono phosphate;N,N-diethylethanamine
OJSWUEWFFWZWMU-YCSZXMBFSA-N
CCN(CC)CC.CN1C=[N+](C2=C1C(=O)NC(=N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)(O)O)OC)O